



Media release

US antitrust authority clears merger of SHL's Raytel Cardiac Services into Philips

Tel Aviv/Zurich, 30 October 2007 – SHL Telemedicine Ltd. (SWX: SHLTN), a leading provider and developer of advanced personal telemedicine solutions, announces that it has been advised by the Pre merger Notification Office of the US Federal Trade Commission that early termination of the U.S. Antitrust Waiting Period has been granted thereby clearing the sale of Raytel Cardiac Services and other ancillary operations comprising SHL's US cardiac monitoring activities to Royal Philips Electronics (NYSE:PHG, AEX:PHI). Earlier this month, SHL and Philips announced this transaction in which SHL will receive around USD 110 million as upfront cash consideration and debt assumption plus participation in future revenues from current Raytel services and certain new products and services for up to 9 years. The transaction is expected to close after approval by SHL's shareholders in a Special General Meeting to be held on November 27th, 2007.

About SHL Telemedicine

SHL Telemedicine Ltd. is a leading provider and developer of advanced personal telemedicine solutions to individuals and to the healthcare community. As a leading provider of remote health services in cardiology and in other medical areas, SHL maintains business operations in the US, Europe and Israel. SHL is listed on the SWX Swiss Exchange, symbol SHLTN. For more information please visit SHL's web site at www.shl-telemedicine.com.

For further information please contact:

- Erez Alroy, Co-CEO, Phone: +972 3561 22 12, ereza@shl-telemedicine.com
- Assistant: Pauline Shavit, Phone: +972 3561 22 12, pauline@shl-telemedicine.com
- Martin Meier-Pfister, The Investor Relations Firm AG, Phone: +41 43 244 81 40, shl@irfirm.biz

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.